Steven Sfamenos
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Steven Sfamenos has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Jun Gu
Cytogenetic Technology Program, School of Health Professions, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
2 shared publications - Zhenya Tang
Department of Pathology, Microbiology and Immunology, University of Nebraska Medical Center, Omaha, NE 68198, USA
2 shared publications - Gokce Altay Toruner
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
1 shared publication - Guilin Tang
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, USA
1 shared publication - Hui Chen
Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas
1 shared publication - Joseph D. Khoury
Department of Pathology, Microbiology, and Immunology, University of Nebraska Medical Center, Omaha, NE
1 shared publication
Latest Publications
- Open Access
- 7 December 2020
- Published by LIDSEN Publishing Inc in OBM Transplantation
- Vol. 04 (04) , 1-11
Donor Cell-Derived Acute Myeloid Leukaemia with 3q26.2 Involvement/MECOM Rearrangement ‐ A Case Report and Literature Review
Donor cell-derived leukaemia (DCL) is an uncommon complication of allogeneic hematopoietic stem cell transplantation (HSCT). DCL might represent up to 5% of the post-HSCT disease relapses, but case numbers reported in the literature might underestimate the frequency. The leukemogenesis of DCL is not well understood due to the limited numbers of cases reported and lack of detailed molecular genetic information from recipients and donors. Although many theories have been proposed for leukemogenesis of DCL, the underlying molecular genetic mechanism are likely heterogeneous. Here we report a case of donor cell-derived acute myeloid leukaemia with 3q26.2 involvement/MECOM rearrangement and chromosome 20q deletion. We also reviewed the literature of previously described DCL cases, and we discussed the risk factors that might be important to the onset of DCL.
- 7 December 2020
- Published by LIDSEN Publishing Inc in OBM Transplantation
- Vol. 04 (04) , 1-11
Open AccessDonor Cell-Derived Acute Myeloid Leukaemia with 3q26.2 Involvement/MECOM Rearrangement ‐ A Case Report and Literature Review
Donor cell-derived leukaemia (DCL) is an uncommon complication of allogeneic hematopoietic stem cell transplantation (HSCT). DCL might represent up to 5% of the post-HSCT disease relapses, but case numbers reported in the literature might underestimate the frequency. The leukemogenesis of DCL is not well understood due to the limited numbers of cases reported and lack of detailed molecular genetic information from recipients and donors. Although many theories have been proposed for leukemogenesis of DCL, the underlying molecular genetic mechanism are likely heterogeneous. Here we report a case of donor cell-derived acute myeloid leukaemia with 3q26.2 involvement/MECOM rearrangement and chromosome 20q deletion. We also reviewed the literature of previously described DCL cases, and we discussed the risk factors that might be important to the onset of DCL.
- Open Access
- 13 May 2020
- Published by LIDSEN Publishing Inc in OBM Genetics
- Vol. 04 (02) , 1-14
HER2 FISH for Breast Cancer: Advances in Quantitative Image Analysis and Automation
Quantitative image analysis of the status of human epidermal growth factor receptor 2 (HER2) by both immunohistochemistry staining and fluorescent in situ hybridization (FISH) is important for the treatment of breast cancer. Guidelines of the American Society for Clinical Oncology and College of American Pathologists, for HER2 FISH, have evolved over time to improve test accuracy, and efforts have been made to better address the problems with the interpretation that are encountered with borderline-positive cases. Standardization and automation of HER2 sample preparation, processing, and digital quantitation are being considered. We compared the manual quantitation of HER2 FISH with automated scoring and reviewed the history and current status of automated scoring of HER2 FISH. We explored areas for the possible automation of the process of HER2 FISH and discussed the latest improvements in quantitative image analysis. We conclude that an integrated review of hematoxylin and eosin staining, immunohistochemistry, and FISH by digital image analysis technology would help pathologists to readily identify tumor areas, differentiate invasive from in situ carcinoma, and to recognize HER2 signal patterns (even in clustered heterogeneity). An integrated system would also allow automatic alerts for discrepancies in results for FISH versus immunohistochemistry, and for tumor histology and grade.
- 13 May 2020
- Published by LIDSEN Publishing Inc in OBM Genetics
- Vol. 04 (02) , 1-14
Open AccessHER2 FISH for Breast Cancer: Advances in Quantitative Image Analysis and Automation
Quantitative image analysis of the status of human epidermal growth factor receptor 2 (HER2) by both immunohistochemistry staining and fluorescent in situ hybridization (FISH) is important for the treatment of breast cancer. Guidelines of the American Society for Clinical Oncology and College of American Pathologists, for HER2 FISH, have evolved over time to improve test accuracy, and efforts have been made to better address the problems with the interpretation that are encountered with borderline-positive cases. Standardization and automation of HER2 sample preparation, processing, and digital quantitation are being considered. We compared the manual quantitation of HER2 FISH with automated scoring and reviewed the history and current status of automated scoring of HER2 FISH. We explored areas for the possible automation of the process of HER2 FISH and discussed the latest improvements in quantitative image analysis. We conclude that an integrated review of hematoxylin and eosin staining, immunohistochemistry, and FISH by digital image analysis technology would help pathologists to readily identify tumor areas, differentiate invasive from in situ carcinoma, and to recognize HER2 signal patterns (even in clustered heterogeneity). An integrated system would also allow automatic alerts for discrepancies in results for FISH versus immunohistochemistry, and for tumor histology and grade.